Comparative Analysis of the Neurochemical Profile and MAO Inhibition Properties of N-(Furan-2-ylmethyl)-N-methylprop-2-yn-1-amine

被引:19
作者
De Deurwaerdere, Philippe [1 ]
Binda, Claudia [2 ]
Corne, Remi [1 ]
Leone, Cosima [3 ]
Valeri, Aurora [4 ]
Valoti, Massimo [3 ]
Ramsay, Rona R. [5 ]
Fall, Yagamare [6 ]
Marco-Contelles, Jose [7 ]
机构
[1] CNRS, UMR CNRS 5293, Inst Malad Neurodegenerat, F-33000 Bordeaux, France
[2] Univ Pavia, Dipartimento Biol & Biotecnol, I-27100 Pavia, Italy
[3] Univ Siena, Dipartimento Sci Vita, I-53100 Siena, Italy
[4] Univ Perugia, Dipartimento Chim Biol & Biotecnol, I-06123 Perugia, Italy
[5] Univ St Andrews, Biomed Sci Res Complex, St Andrews KY16 9ST, Fife, Scotland
[6] Univ Vigo, Dept Quim Organ, Vigo 36310, Spain
[7] CSIC, IQOG, Lab Med Chem, E-28006 Madrid, Spain
关键词
Propargylamines; crystallography; monoamine neurochemistry; neuroprotection; Alzheimer's disease; enzymology; MONOAMINE-OXIDASE-A; QUANTITATIVE ENZYME AUTORADIOGRAPHY; IN-VITRO; L-DOPA; ALZHEIMERS-DISEASE; METABOLISM; SEROTONIN; STRIATUM; BRAIN; SELEGILINE;
D O I
10.1021/acschemneuro.6b00377
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The regulation of brain monoamine levels is paramount for cognitive functions, and the monoamine oxidase (MAO A and B) enzymes play a central role in these processes. The aim of this study was to evaluate whether the procognitive properties exerted by propargylamine N-(furan-2-ylmethyl)-Nmethylprop-2-yn-1-amine (F2MPA) are related to changes in monoamine content via MAO inhibition. In vivo microdialysis and ex vivo amine metabolite measurement demonstrated region specific alterations in monoamine metabolism that differ from both of the classic MAO A and MAO B inhibitors, clorgyline and L-deprenyl, respectively. Although all the inhibitors (1 and 4 mg/kg) increased cortical serotonin tissue content, only F2MPA increased the levels of cortical noradrenaline. In the striatum, clorgyline (1 mg/kg), but not F2MPA (1 mg/kg), reduced extracellular levels of dopamine metabolites at rest or stimulated by the intrastriatal application of the MAO substrate 3-methoxytyramine. In vitro, F2MPA exhibited a low affinity toward MAO B and MAO A. Nonetheless, it modified the B form of MAO, forming a flavin adduct structurally similar to that with deprenyl. F2MPA was rapidly metabolized in the presence of rat but not human microsomes, producing a hydroxylated derivative. In conclusion, the effect of F2MPA on cognition may arise from monoaminergic changes in the cortex, but the role of MAO in this process is likely to be negligible, consistent with the poor affinity of F2MPA for MAO.
引用
收藏
页码:1026 / 1035
页数:10
相关论文
共 43 条
[1]   CDNA CLONING OF HUMAN-LIVER MONOAMINE OXIDASE-A AND OXIDASE-B - MOLECULAR-BASIS OF DIFFERENCES IN ENZYMATIC-PROPERTIES [J].
BACH, AWJ ;
LAN, NC ;
JOHNSON, DL ;
ABELL, CW ;
BEMBENEK, ME ;
KWAN, SW ;
SEEBURG, PH ;
SHIH, JC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (13) :4934-4938
[2]  
Baranczewski P, 2006, PHARMACOL REP, V58, P453
[3]   Lights and Shadows on Monoamine Oxidase Inhibition in Neuroprotective Pharmacological Therapies [J].
Binda, Claudia ;
Milczek, Erika M. ;
Bonivento, Daniele ;
Wang, Jin ;
Mattevi, Andrea ;
Edmondson, Dale E. .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2011, 11 (22) :2788-2796
[4]   In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism [J].
Brannan, T ;
Prikhojan, A ;
MartinezTica, J ;
Yahr, MD .
JOURNAL OF NEURAL TRANSMISSION-PARKINSONS DISEASE AND DEMENTIA SECTION, 1995, 10 (2-3) :79-89
[5]  
Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V55, P760
[6]   Pharmacological Treatment of Parkinson Disease A Review [J].
Connolly, Barbara S. ;
Lang, Anthony E. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (16) :1670-1683
[7]  
Copeland RA, 2000, ENZYMES PRACTICAL IN
[8]  
Cruciani Gabriele, 2013, Drug Discov Today Technol, V10, pe155, DOI 10.1016/j.ddtec.2012.11.001
[9]   DP7, a novel dihydropyridine multidrug resistance reverter, shows only weak inhibitory activity on human CYP3A enzyme(s) [J].
D'Elia, Paolo ;
De Matteis, Francesco ;
Dragoni, Stefania ;
Shah, Anamik ;
Sgaragli, Giampietro ;
Valoti, Massimo .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 614 (1-3) :7-13
[10]   Three-dimensional structure of human monoamine oxidase A (MAO A): Relation to the structures of rat MAO A and human MAO B [J].
De Colibus, L ;
Li, M ;
Binda, C ;
Lustig, A ;
Edmondson, DE ;
Mattevi, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (36) :12684-12689